The PLZF gene was identi®ed ®rst by its fusion with the retinoic acid receptor a gene in the t(11;17) translocation associated with a retinoic acid resistant form of acute promyelocytic leukemia (APL). It encodes a kruÈppel-like zinc ®nger protein with a POZ domain shared with a subset of regulatory proteins including the BCL6 leukemogenic protein. PLZF, like BCL6, strongly represses transcription initiated from dierent promoters. Here we show that PLZF associates in vitro and in vivo with the Mad co-repressor mSin3A and the histone deacetylase HDAC1. Two domains in PLZF and the PAH1 structure of mSin3A mediate these interactions. Trichostatin A, a speci®c inhibitor of histone deacetylases, signi®cantly reduces PLZF repression. These data strongly suggest that, like nuclear receptors and Mad, PLZF represses transcription by recruiting a histone deacetylase through the SMRT-mSin3-HDAC co-repressor complex. We also show that BCL6 associates with HDAC1 indicating that this type of regulation might be common to POZ/Zinc ®nger proteins involved in human leukemias. This work supports a role for deregulated histone deacetylation in the development of both lymphoid and myeloid neoplasia in human and suggests that targeted histone deacetylase inhibitors may be useful for treatment of certain types of malignancies.
Introduction
Acute promyelocytic leukemia (APL) is associated in 495% of patients with the consistent chromosomal translocation t(15;17) that fuses the PML protein to the retinoic acid receptor a (RARa) (De TheÂ et al., 1991; Goddard et al., 1991; Kakizuka et al., 1991; Pandol® et al., 1991) . This disease is uniquely sensitive to retinoic acid (RA) treatment that leads to morphological complete remissions by inducing the dierentiation of the leukemic cells into mature granulocytes. In a small percentage of APL cases, the variant t(11;17) translocation gives rise to a dierent chimaeric protein that fuses the PLZF (Promyelocytic Leukemia Zinc Finger) protein to the exact same portion of RARa (Chen et al., 1993) . Interestingly, in addition to the PLZF ± RARa protein, the reciprocal RARa ± PLZF is also expressed from the derivative 17q-chromosome (Chen et al., 1993) . However, APL associated with this variant translocation corresponds to a distinct clinical syndrome which, unlike the typical t(15;17) APL, fails to respond to RA therapy (Guidez et al., 1994; Licht et al., 1995) .
The PLZF gene encodes a KruÈppel-like protein containing nine C-terminal zinc ®nger motifs and a conserved N-terminal POZ domain involved in protein ± protein interactions (Bardwell and Treisman, 1994) . PLZF is expressed in a highly tissue-speci®c manner. During murine development, it is expressed at rhombomere boundaries in the hindbrain region . PLZF is also expressed in multipotent hematopoietic progenitor cells and its expression is down-regulated during myeloid maturation (Chen et al., 1993; Reid et al., 1995) . Accordingly, PLZF levels decline in APL cells in response to RA-induced dierentiation. Taken together, these data suggest an important role of PLZF in both central nervous system development and early hematopoiesis. Although the PLZF natural target genes have not yet been identi®ed, a high anity PLZF-binding site was recently isolated in the lexA operator (Sitterlin et al., 1997) . When fused to a GAL4 DNA-binding domain, PLZF strongly represses transcription from a GAL4-dependent reporter (Hong et al., 1997) . In addition, the native PLZF protein has been shown to repress cyclin A expression, possibly through binding a speci®c TA-rich motif in the cyclin A promoter (Yeyati et al., 1997) . Together, these results indicate that PLZF functions as a transcriptional repressor. Interestingly, another POZ/ Zinc ®nger KruÈppel-like protein, the BCL6 oncoprotein, which also behaves as a transcriptional repressor was shown to be implicated in human leukemogenesis. Indeed, a high proportion of diuse large cell lymphoma, a particular class of non-Hodgkin's lymphoma, harbor translocations or mutations in the BCL6 gene (Kerckaert et al., 1993; Ye et al., 1993) which presumably deregulate its expression. The ability of BCL6 to repress transcription is likely to play a major role in the transformation process (Chang et al., 1996; Deweindt et al., 1995; Seyfert et al., 1996) .
Retinoic acid receptors (RARs) belong to the superfamily of nuclear receptors that function as ligand-dependent transcription factors (Mangelsdorf and Evans, 1995; Kastner et al., 1995) . They bind as heterodimers with the retinoid X receptor (RXR) to cis-acting DNA response elements present in the promoter region of the target genes. Transcriptional squelching between members of the nuclear receptor family suggested the existence of intermediary cofactors. A number of nuclear receptor interacting proteins have been characterized that speci®cally bind to the hormone-binding domain of the receptor in the presence of ligand, some of them, including histone acetyltransferases like CBP and its homolog p300, P/ CAF and ACTR were shown to behave unequivocally as true co-activators (Chen et al. (1997) and references therein). Conversely, in the absence of ligand, RARs (and their related thyroid hormone receptors TRs) behave as transcriptional repressors. This eect is thought to be mediated through binding to the SMRT/N-CoR family of co-repressors (Chen and Evans, 1995; Horlein et al., 1995; Sande and Privalsky, 1996) . Indeed SMRT and N-CoR interact strongly with unliganded receptors and are released upon ligand binding. A series of recent reports (Alland et al., 1997; Hassig et al., 1997; Heinzel et al., 1997; Kadosh and Struhl, 1997; Laherty et al., 1997; Zhang et al., 1997) have shown that SMRT/ N-CoR co-repressors are part of a multiprotein complex including the Mad co-repressors mSin3A and B (Ayer et al., 1995; Schreiber-Agus et al., 1995) and the histone deacetylases HDAC1/HD1 and HDAC2/mRPD3 (Taunton et al., 1996; Yang et al., 1996) . These studies, that strengthen the major role of histone acetylation/deacetylation in transcriptional regulation, provide the basis for the existence of a common repression pathway between nuclear receptors and basic region-helix ± loop ± helix-leucine zipper (bHLH-Zip) proteins.
Several factors led us to explore whether the POZ/ Zinc ®nger protein PLZF may function as a trancriptional silencer through recruitment of the mSin3-histone deacetylase co-repressor complex (see Pazin and Kadonaga, 1997; Wole, 1997) . Using the mammalian two hybrid system, we recently found that PLZF was able to associate with the nuclear receptor SMRT co-repressor (Hong et al., 1997) . The emerging role of modulators of chromatin architecture in cancer pathogenesis (Wole, 1997) further suggested that histone deacetylase may be an essential component of this complex. Here we report that mSin3 and HDAC1 interact with PLZF and that the histone deacetylase inhibitor trichostatin A interferes with PLZF-mediated transcriptional repression. We also demonstrate that the BCL6 oncoprotein interacts with HDAC1 in vivo indicating that repression by POZ/Zinc ®nger proteins may involve recruitment of the same mSin3-HDAC ± SMRT co-repressor complex as required for repression by nuclear receptors and Mad. These data strongly suggest that alterations in chromatin modeling may play an important role in human leukemogenesis.
Results and discussion
PLZF interacts with mSin3A and HDAC1 in vitro To determine whether the PLZF protein may interact in vitro with mSin3 and HDAC1, we performed pull down experiments. Glutathione S-transferase (GST) fusion proteins containing either the ®rst 456 amino acids (aa) of PLZF, the PLZF domain found in the PLZF ± RARa hybrid (see Figure 1a) , or the unrelated ICPO protein were expressed in bacteria, puri®ed and used to bind 35 S-labeled mSin3A, mSin3B, HDAC1 as well as a`control' SP100 protein. As shown in Figure  1b , none of the radiolabeled proteins were signi®cantly pulled down by GST ± ICPO (lanes 6, 9 and 12). However, under the same conditions, mSin3A and HDAC1 strongly bound to GST ± PLZF 1 ± 456 (lanes 5 and 11), suggesting that both mSin3A and HDAC1 directly and independently interact with PLZF. On the contrary, very little binding was observed between mSin3B and PLZF (lane 8), indicating that, by contrast to mSin3A, mSin3B interacts poorly with PLZF in vitro. Interestingly, a dierent behavior among the two mSin3 isoforms was also reported in the case of SMRT. Indeed, if SMRT can form strong association with mSin3A, it fails to interact directly with mSin3B . To now verify the interaction between PLZF and HDAC1 in the context of the entire PLZF protein, a reciprocal pull down experiment was conducted using a GST ± HDAC1 matrix and the radiolabeled full length PLZF protein. As expected, PLZF 1 ± 673 bound speci®cally to GST ± HDAC1 but not to GST ± ICPO ( Figure 1c ).
POZ/Zinc ®nger proteins associates with mSin3A and B and HDAC1 in vivo
Low-stringency co-immunoprecipitation was used to determine whether PLZF interacts with mSin3A and B and HDAC1 in vivo (Figure 2a Altogether, these data demonstrate that PLZF exists in a complex with HDAC1 and both forms of mSin3 in vivo, with mSin3A showing signi®cantly stronger binding to PLZF than mSin3B. The above ®ndings suggested that other POZ/Zinc ®nger proteins also may form a complex with mSin3A and HDAC1 in vivo. When BCL6 was co-expressed with HDAC1 FLAG in vivo, anti-FLAG antibody immunoprecipitates BCL6 as detected using an anti-BCL6 antibody (Figure 2c, lane 3) . This co-immunoprecipitation was not observed when BCL6 was transfected alone (Figure 2c, lane 2) . In contrast, coexpression of mSin3A FLAG or mSin3B FLAG along with BCL6 failed to detect a strong interaction between BCL6 and either mSin3A or mSin3B (data not shown). These results suggest that recruitment of histone deacetylase may be a common mechanism of repression among the family of POZ/Zinc ®nger proteins.
Mapping of the interaction domains
To delineate the precise region(s) in the N-terminal moiety of the PLZF sequence that mediate(s) interaction with mSin3A and HDAC1, GST fusion proteins of various PLZF derivatives were used in pull down experiments (Figure 3) . PLZF constructs encompassing the POZ domain from aa 1 to 120 or 1 to 137 are sucient to confer interaction with both mSin3A (lanes 3 and 4) and HDAC1 (lanes 10 and 11). However, the remainder of the PLZF sequence (aa 121 ± 456) (lanes 5 and 12), excluding the two zinc ®nger motifs (aa 365 ± 456) (lanes 6 and 13), also shows autonomous association with mSin3A and HDAC1. These results reveal that, in addition to the N-terminal POZ motif, a second interaction domain, whose precise boundaries remain to be determined, resides within the PLZF region encompassing aa 121 ± 364. They also indicate that PLZF uses the two same domains to interact with mSin3A and HDAC1. To explore the possibility that the binding of PLZF to one of the two protein partners may interfere with its binding to the other, mSin3A and HDAC1 were in vitro co-translated and incubated together on the GST ± PLZF 1 ± 456 matrix. As shown in Figure 1d , the eciency of the pull down was barely weaker under these conditions than that observed for each protein alone (compare with Figure   Figure 1 PLZF interacts in vitro with mSin3A and HDAC1. (a) Schematic representation of the RARa, RARa ± PLZF, PLZFRARa, PLZF and BCL6 proteins. Sequences derived from RARa are represented as hatched boxes and are subdivided into domains A to F with the receptor regions involved in DNA-and hormone-binding indicated above the schema. The POZ domain (Bardwell and Treisman, 1994) and the zinc ®nger motifs (Z) in PLZF and BCL6 are indicated. Translocation t(11;17) results in the fusion of the N-terminus of PLZF up to the second zinc ®nger motif to domains B-F of RARa. The reciprocal protein contains the A domain of RARa linked to the seven C-terminal zinc ®ngers of PLZF (Chen et al., 1993) . The number of amino acids in each protein are indicated. (b) Binding of mSin3A and HDAC1 to PLZF in vitro. Interaction of the indicated 35 S-labeled SP100, mSin3A, mSin3B and HDAC1 proteins with the GST ± PLZF 1 ± 456 or the unrelated GST ± ICPO fusions. Twenty per cent of input protein is shown. (c) Binding of full length PLZF to HDAC1 in vitro. GST interaction assay of radiolabeled PLZF 1 ± 673 protein with GST ± HDAC1. GST ± ICPO was used as a negative control. The input lane shows the radiolabeled proteins. (d) PLZF forms a ternary complex with mSin3A and HDAC1 in vitro. GST ± PLZF 1 ± 456 and GST ± ICPO (as a negative control) were used as anity matrices for in vitro co-translated and radiolabeled mSin3A and HDAC1. Ten per cent of the input is shown 1b) suggesting that mSin3A and HDAC1 do not heavily compete for binding to PLZF, nor do they synergize. The ®ne mapping of the PLZF interaction domains with each of the two mSin3A and HDAC1 proteins should help in clarifying whether these interactions are overlapping or just adjoining.
The Sin3 proteins contain four paired amphipathic helices (PAH 1 ± 4 ) which are likely to mediate protein ± protein interactions (Wang et al., 1990) . The yeast twohybrid system was used to map the speci®c domain of mSin3A that interacts with PLZF. This was conducted using a GAL4 activation domain fusion of PLZF 1 ± 435 and LexA DNA-binding domain fusions of various mSin3A fragments. Figure 3b shows that amino acids 69 ± 316 of mSin3A, encompassing PAH1, interact strongly with PLZF. In contrast, no interaction is observed with mSin3A segments containing PAH2, PAH3 or PAH4 (aa 266 ± 479, aa 398 ± 533 and aa 534 ± 1274 respectively). Thus mSin3A interacts with PLZF though its PAH1 domain. It is noteworthy that the same motif was shown to mediate interactions with SMRT in yeast and with the Cterminal domain of N-CoR in yeast and in vitro (Alland et al., 1997; Heinzel et al., 1997) . In a similar set of experiments, we also examined whether mSin3B associates with PLZF in yeast. Similarly to what observed for mSin3A, the PAH1 domain of mSin3B (aa 2 ± 125) was found to interact with PLZF, albeit less eciently, while PAH2, PAH3 and PAH4 (aa 119 ± 297, 298 ± 390 and 383 ± 954 respectively) showed no association (Figure 3c ).
Histone deacetylase activity is required for transcriptional repression by PLZF
To determine whether the recruitment of histone deacetylases plays a role in PLZF-mediated repression in vivo, we analysed the eect of trichostatin A (TSA), a (Hong et al., 1997) or the`control' ICPO. Twenty per cent of the input is shown and the position of the radiolabeled proteins are marked on the right. Localization of the mSin3A (b) and mSin3B (c) domains required for PLZF interactions. Various LexA (DBD)-mSin3A and -mSin3B baits (Alland et al., 1997) were used along with the GAL4(AD) ± PLZF 1 ± 435 or the`control' GAL4(AD)-PRP9 activators to localize the PLZF interaction domain of mSin3 in yeast cells. +++, a LacZ phenotype that is equivalent to that observed for the control PRP9/PRP21 interaction used as a positive control in yeast speci®c inhibitor of histone deacetylases (Yoshida et al., 1995) . Consistent with our previous observations (Hong et al., 1997) , arti®cial recruitment of PLZF as a GAL4 fusion protein on a reporter gene containing ®ve GAL4-binding sites in front of a b-globin promoter-CAT fusion (56GAL-bG-CAT) resulted in a strong decrease in the transcriptional activity of the reporter in CCL13 cells (Figure 4a) . A duplicate set of transfections were treated with 100 ng/ml TSA for 24 h prior to harvesting. Although a non negligible stimulation of the expression of the reporter gene was observed with the GAL4 vector alone, the derepression induced by TSA was &fourfold with the GAL4 ± PLZF protein, indicating that histone deacetylation plays a direct role in PLZF-mediated repression. However, derepression was not complete as indicated by a residual &threefold repressing activity, suggesting that, as already postulated for mSin3 and NCoR ((Pazin and Kadonaga, 1997; Wole, 1997) and references therein), PLZF might use other mechanisms in addition to histone deacetylation to repress transcription.
We then wished to investigate the eect of TSA on the transcriptional repression mediated by the native PLZF protein when bound to DNA through its own zinc ®nger binding domain. For this purpose, two dierent reporter genes were utilized. The ®rst reporter plasmid contained 7.5 kb of the cyclin A promoter region (Henglein et al., 1994) upstream of the luciferase gene (CyclinApr-Luc). The expression of cyclin A is down-regulated by PLZF and a PLZF-binding site, similar to that selected from a pool of random oligonucleotides, was recently identi®ed in the cyclin A promoter (Yeyati et al., 1997) . The second reporter (8OP-SV-Luc), consisted of a speci®c PLZF target site present in the lexA operator sequences (Sitterlin et al., 1997) in front of an SV40 promoter-Luc fusion. When the PLZF expression vector was cotransfected with the CyclinAPr-Luc (Figure 4b) or the 8OP-SV-Luc reporters (Figure 4c ), a substantial decrease in the luciferase activity (four-and eightfold respectively) was noted, consistent with the expected repressing properties of PLZF. The repression was dependent upon the presence of the PLZF DNA-binding site in the indicator genes (not shown). Treatment with TSA derepressed the activity of PLZF&threefold in both cases indicating that repression by PLZF on its cognate sites requires histone deacetylase activity. However, this mechanism may not be fully responsible for PLZF repression since, as in the case of the GAL4 ± PLZF fusion, a low but reproducible level of repression persisted after TSA treatment.
Our data suggest that the repressing activity of PLZF is principally mediated via association with mSin3 and HDAC1. Removal of the N-terminal moiety of PLZF, that contains mSin3A/HDAC1 interaction domains, would thus be expected to result in a complete loss of repression. To test this hypothesis, we analysed the transcriptional properties of the reciprocal RARa ± PLZF fusion protein expressed in the t(11;17)-associated APL syndrome. This chimaera consists of the ®rst 60 amino acids of RARa (referred to as the A region) fused to the seven C-terminal zinc ®ngers of PLZF (see Figure 1a) . As the last ®ve zinc ®ngers have been shown to be sucient for DNA-binding activity on the lex A operator (Sitterlin et al., 1997) , the 8OP-SV-Luc reporter plasmid was used in this experiment. As shown in Figure 4c , no decrease in the luciferase activity from the reporter gene was observed after transfection of RARa ± PLZF indicating that the fusion protein has lost its ability to repress transcription. As expected, there was almost no eect of TSA on the activity of the reporter gene under these conditions.
Conclusion
In this report, we demonstrate that mSin3A and HDAC1 strongly bind to PLZF and that the histone deacetylase inhibitor trichostatin A interferes with PLZF-mediated transcriptional repression. Together with our recent ®nding that PLZF associates with SMRT (Hong et al., 1997) , these data strongly suggest that PLZF mediates its silencing eect, at least in part, by associating with the essential components of the mSin3-HDAC ± SMRT corepressor complex. We also show that the BCL6 oncoprotein interacts with HDAC1 in vivo implicating (pCH110) construct. The reporter and expression constructs are described in the Materials and methods. The transcriptional activity of the various PLZF proteins was determined 48 h after transfection by measuring CAT or luciferase activities of transfected cells following an 24 h treatment with 0 (7) or 100 ng/ml TSA (+). Transfection eciencies were normalized using b-galactosidase assay. A notable increase of the b-gal activity was observed in a reproducible manner after TSA treatment. This eect might be partly explained by a particular sensitivity to histone deacetylation of the SV40 promoter present in the internal pCH110 control vector. Transfections were repeated at least three times in duplicate histone deacetylation as a potential mechanism for repression mediated by POZ/Zinc ®nger proteins. Our data, that provide a molecular basis for the function of these proteins in transcriptional repression and leukemogenesis, strengthen the role of chromatin remodeling factors in human cancer pathogenesis.
It is intriguing that the t(11;17)-associated PLZF ± RARa oncoprotein fuses two proteins, PLZF and RARa, that are both able to interact independently with the mSin3-HDAC ± SMRT co-repressor complex. However, if the RARa part exhibits a ligand-labile interaction with this complex, the retinoic acidinsensitive interaction domain in PLZF stabilizes the association of the PLZF ± RARa fusion protein with co-repressors, in particular with HDAC1 (GD and AD, unpublished results). It is thus tempting to speculate that PLZF ± RARa may contribute to leukemogenesis by repressing, in a constitutive manner, the expression of retinoic acid target genes presumably involved in myeloid cell dierentiation. The ligand-refractory, corepressor binding properties of PLZF may partly explain the lack of responsiveness to retinoic acid of APL patients expressing PLZF ± RARa. In this context, one might hypothesize that treatment with speci®c HDAC inhibitors should help in releasing the blockage of dierentiation of the leukemic cells bearing the t(11;17) translocation. Interestingly, histone deacetylase inhibitor sodium butyrate or trichostatin A have been shown to synergize with retinoic acid to induce dierentiation of the human myeloid leukemia HL60 cells (Breitman and He, 1990; Nagy et al., 1997) . Thus, the use of well targeted histone deacetylase inhibitors may prove to be an eective approach for oncologic therapy in the near future.
Materials and methods

In vitro translation and GST pull down assays
The dierent GST ± PLZF constructs in the pGEX ± KG vector were reported previously (Hong et al., 1997) . The GST ± ICPO protein was generated by cloning the region encoding aa 549 ± 779 of the HSV ICPO (provided by R Everett) in pGEX ± 2TK (Pharmacia). The GST fusion protein of the full length HDAC1 (aa 2 ± 482) in pGEX 5X-1 vector was constructed using standard procedures. The plasmids used for in vitro translation were generated by subcloning the full length SP100, mSin3A, mSin3B, HDAC1 and PLZF cDNAs in the pSG5 (Stratagene), pcDNA3 (Invitrogen) or pGEM (Promega) vectors. GST fusion proteins were expressed in BL21 cells and bound to glutathione sepharose 4B beads (Pharmacia).
35 S-methionine radiolabeled mSin3A, mSin3B, HDAC1, SP100 and PLZF proteins were synthesized using the TNT coupled in vitro transcription and traduction system (Promega). Radiolabeled proteins were incubated 2 h with the GST fusion proteins at 48C with gentle mix in PBS plus 100 mM KCl and 0.5% NP40. Beads were then extensively washed in the same buer and the bound proteins were eluted in Laemmli buer, fractionnated on SDS ± PAGE protein gels and visualized by autoradiography.
Immunoprecipitations
Subcon¯uent 293T cells were transfected with 3 mg each of the appropriate expression constructs shown in Figure 2 and 80 mg of Lipofectamine reagent (Gibco ± BRL). After 48 h, immunoprecipitations under low stringency conditions were performed as described (Alland et al., 1997) , resolved by SDS ± PAGE, transferred to nitrocellulose and detected by Western blotting using anti-FLAG M2 (Kodak), anti-HA (Santa Cruz) and anti-BCL6 C19 (Santa Cruz) antibodies. The HA-tagged PLZF expression vector in pSG5 (Stratagene) encoding residues 1 ± 673 of PLZF followed by the HA epitope was generated by standard PCR-based methodology. The BCL6 expression vector in pCGNm2 was provided by L Staudt. The FLAGtagged mSin3A expression construct in pEBB was described previously (Rao et al., 1996) . The FLAG-tagged mSin3B expression vector in pcDNA3 (Invitrogen) encoding residues 1 ± 954 of mSin3B followed by the FLAG epitope was generated by standard PCR-based methodology. The HDAC1 FLAG expression construct in pBJ5 was provided by S Schreiber.
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